Company news

AN2 Therapeutics, Inc. news in 2026

AN2 Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

November 4, 2026

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

November 4, 2026

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

November 2, 2026

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

October 23, 2026

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

October 21, 2026

AN2 Therapeutics to Participate at Upcoming Investor Conferences

October 20, 2026

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

September 28, 2026

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

September 16, 2026

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

August 31, 2026

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

August 24, 2026

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

August 11, 2026

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

June 3, 2026

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

May 21, 2026

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

May 11, 2026

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 7, 2026

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

March 30, 2026

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

March 16, 2026

AN2 Therapeutics Announces $40 Million Private Placement Financing

March 8, 2026

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

March 2, 2026

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

February 17, 2026

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

January 12, 2026

Decks in 2026